[New immunotherapy approaches for gastrointestinal cancer].

IF 0.1 Q4 GASTROENTEROLOGY & HEPATOLOGY
Gastroenterologie Pub Date : 2025-01-01 Epub Date: 2025-04-04 DOI:10.1007/s11377-025-00895-y
Bernd Heinrich, Tim F Greten
{"title":"[New immunotherapy approaches for gastrointestinal cancer].","authors":"Bernd Heinrich, Tim F Greten","doi":"10.1007/s11377-025-00895-y","DOIUrl":null,"url":null,"abstract":"<p><p>Immunotherapy is part of the standard therapy for gastrointestinal (GI) tumors. Nevertheless, response rates are rather low. Current studies are investigating the optimal timing and patient clientele for immunotherapy. Combinations of approved drugs are also being tested. The development of new therapeutic approaches is equally important, e.g. to overcome primary and secondary resistance. Antibody-mediated immune checkpoint inhibitor (ICI) therapy is constantly being expanded. New target molecules on immune and tumor cells are intended to further improve the immune response by activating immune cells or blocking an inhibitory signaling pathway. The combination of antibody with drug in the sense of an immunoconjugate is possible. Modifications of the antibody structure are being tested for improved efficacy and an extended range of applications. Cellular strategies, such as adoptive cell transfer or the application of genetically modified T cells, are currently being tested in studies for use in GI tumors. T cells with chimeric antigen receptors (CAR), which recognize and attack certain proteins on tumor cells, are a promising approach. Viruses that can destroy tumor cells due to natural reproductive behavior or genetic alterations are used as oncolytic viruses in GI oncology, but pose challenges due to low immunogenicity or non-specific effects. Another difficulty is the development of sensitive and specific biomarkers that predict response and efficacy of immunotherapies. This review article aims to provide a glimpse into the crystal ball and present and discuss new promising immunotherapeutic approaches.</p>","PeriodicalId":29716,"journal":{"name":"Gastroenterologie","volume":"20 3","pages":"199-207"},"PeriodicalIF":0.1000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150865/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastroenterologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s11377-025-00895-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/4 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Immunotherapy is part of the standard therapy for gastrointestinal (GI) tumors. Nevertheless, response rates are rather low. Current studies are investigating the optimal timing and patient clientele for immunotherapy. Combinations of approved drugs are also being tested. The development of new therapeutic approaches is equally important, e.g. to overcome primary and secondary resistance. Antibody-mediated immune checkpoint inhibitor (ICI) therapy is constantly being expanded. New target molecules on immune and tumor cells are intended to further improve the immune response by activating immune cells or blocking an inhibitory signaling pathway. The combination of antibody with drug in the sense of an immunoconjugate is possible. Modifications of the antibody structure are being tested for improved efficacy and an extended range of applications. Cellular strategies, such as adoptive cell transfer or the application of genetically modified T cells, are currently being tested in studies for use in GI tumors. T cells with chimeric antigen receptors (CAR), which recognize and attack certain proteins on tumor cells, are a promising approach. Viruses that can destroy tumor cells due to natural reproductive behavior or genetic alterations are used as oncolytic viruses in GI oncology, but pose challenges due to low immunogenicity or non-specific effects. Another difficulty is the development of sensitive and specific biomarkers that predict response and efficacy of immunotherapies. This review article aims to provide a glimpse into the crystal ball and present and discuss new promising immunotherapeutic approaches.

[胃肠道肿瘤的新免疫治疗方法]。
免疫治疗是胃肠道肿瘤标准治疗的一部分。然而,回复率相当低。目前的研究正在调查免疫治疗的最佳时机和患者。批准药物的组合也在测试中。开发新的治疗方法同样重要,例如克服原发性和继发性耐药性。抗体介导的免疫检查点抑制剂(ICI)治疗正在不断扩大。免疫细胞和肿瘤细胞上的新靶分子旨在通过激活免疫细胞或阻断抑制信号通路来进一步改善免疫反应。在免疫偶联物的意义上,抗体与药物的结合是可能的。正在对抗体结构的修改进行测试,以提高功效和扩大应用范围。细胞策略,如过继细胞转移或转基因T细胞的应用,目前正在研究中用于胃肠道肿瘤的测试。具有嵌合抗原受体(CAR)的T细胞可以识别和攻击肿瘤细胞上的某些蛋白质,是一种很有前途的方法。由于自然繁殖行为或遗传改变而能破坏肿瘤细胞的病毒在胃肠道肿瘤中被用作溶瘤病毒,但由于低免疫原性或非特异性作用而构成挑战。另一个困难是开发敏感和特异性的生物标志物来预测免疫疗法的反应和疗效。这篇综述文章旨在提供对水晶球的一瞥,并提出和讨论新的有前途的免疫治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.30
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信